Pyxis Oncology, Inc. Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Pyxis Oncology, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2024-12-31 was $47.00K, a 74.07% increase year-over-year.
- Pyxis Oncology, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2024-09-30 was $72.00K, a 31.43% decline year-over-year.
- Pyxis Oncology, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2024-06-30 was $105.00K.
- Pyxis Oncology, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2023-12-31 was $27.00K.
- Pyxis Oncology, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2025 was $108.00K, a 51.79% decline from fiscal 2024.
- Pyxis Oncology, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2024 was $224.00K, a 69.70% increase from fiscal 2023.
- Pyxis Oncology, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2023 was $132.00K.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2025-12-31 | $108.00K 10-K · filed 2026-03-23 | |
| 2024-12-31 | $47.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $224.00K 10-K · filed 2026-03-23 |
| 2024-09-30 | $72.00K 10-Q · filed 2025-11-03 | |
| 2024-06-30 | $105.00K 10-Q · filed 2025-08-14 | |
| 2023-12-31 | $27.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $132.00K 10-K · filed 2025-03-18 |
| 2023-09-30 | $105.00K 10-Q · filed 2024-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |